Nivolumab-Induced Diabetic Ketoacidosis: A Case Report

TL;DR

This case report describes a rare side effect of nivolumab, a drug used in autoimmune diseases, causing diabetic ketoacidosis in a patient with adrenal insufficiency.

Contribution

The novelty lies in reporting a rare adverse event of nivolumab-induced diabetic ketoacidosis in a patient with a history of adrenal insufficiency.

Findings

Nivolumab therapy was associated with diabetic ketoacidosis in a patient with adrenal insufficiency.

Symptoms included hyperglycemia, metabolic acidosis, and ketosis after 12 cycles of treatment.

Prompt recognition and management are essential to prevent complications from this rare side effect.

Abstract

Nivolumab, an investigational monoclonal antibody targeting a specific immune pathway, has shown promise in treating various autoimmune diseases. However, like other immunomodulatory agents, it has potential side effects. This case report describes a rare adverse event of nivolumab-induced diabetic ketoacidosis (DKA) in a patient with a history of adrenal insufficiency secondary to nivolumab. The patient presented with symptoms of hyperglycemia, metabolic acidosis, and ketosis after receiving nivolumab therapy for 12 cycles. Prompt recognition and management of nivolumab-induced DKA are crucial to prevent complications and ensure patient safety.